全文获取类型
收费全文 | 2871篇 |
免费 | 168篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 52篇 |
妇产科学 | 69篇 |
基础医学 | 296篇 |
口腔科学 | 84篇 |
临床医学 | 230篇 |
内科学 | 904篇 |
皮肤病学 | 45篇 |
神经病学 | 307篇 |
特种医学 | 67篇 |
外科学 | 344篇 |
综合类 | 13篇 |
预防医学 | 97篇 |
眼科学 | 23篇 |
药学 | 227篇 |
中国医学 | 1篇 |
肿瘤学 | 273篇 |
出版年
2023年 | 17篇 |
2022年 | 26篇 |
2021年 | 67篇 |
2020年 | 46篇 |
2019年 | 48篇 |
2018年 | 77篇 |
2017年 | 58篇 |
2016年 | 63篇 |
2015年 | 83篇 |
2014年 | 133篇 |
2013年 | 150篇 |
2012年 | 211篇 |
2011年 | 189篇 |
2010年 | 128篇 |
2009年 | 118篇 |
2008年 | 212篇 |
2007年 | 226篇 |
2006年 | 182篇 |
2005年 | 192篇 |
2004年 | 153篇 |
2003年 | 118篇 |
2002年 | 118篇 |
2001年 | 44篇 |
2000年 | 41篇 |
1999年 | 28篇 |
1998年 | 25篇 |
1997年 | 24篇 |
1996年 | 20篇 |
1995年 | 13篇 |
1994年 | 15篇 |
1993年 | 12篇 |
1992年 | 23篇 |
1991年 | 14篇 |
1990年 | 12篇 |
1989年 | 16篇 |
1988年 | 15篇 |
1987年 | 13篇 |
1986年 | 14篇 |
1985年 | 10篇 |
1984年 | 9篇 |
1983年 | 10篇 |
1982年 | 7篇 |
1981年 | 9篇 |
1980年 | 7篇 |
1979年 | 4篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1974年 | 10篇 |
1970年 | 3篇 |
1966年 | 3篇 |
排序方式: 共有3052条查询结果,搜索用时 46 毫秒
1.
Alessandro Vatrella Angelantonio Maglio Corrado Pelaia Girolamo Pelaia Carolina Vitale 《Expert opinion on pharmacotherapy》2020,21(12):1505-1515
ABSTRACT
Introduction
‘Critical Asthma Syndrome’ (CAS) is an umbrella term proposed to include several forms of asthma, responsible for acute and life-threatening exacerbations. CAS requires urgent and adequate supportive and pharmacological treatments to prevent serious outcomes. 相似文献2.
3.
D. Sforza G. Iaria L. Petagna A. Parente A. Anselmo F. Sergi S. Marzio F. Corrado S. Telli T.M. Manzia G. Tisone 《Transplantation proceedings》2019,51(1):140-142
Background
One daily dose of tacrolimus (QDT) improves adherence in kidney transplant (KT) recipients. A switch from twice-daily tacrolimus (BDT) to QDT showed similar efficacy and safety.Methods
The aim of our study was to demonstrate the long-term efficacy and safety of switching from BDT to QDT in KT recipients. Preliminary results have already been published. Forty-one patients (34 men and 7 women), mean age at KT of 43.9 ± 12.7 years, underwent a 1:1 dose switch from BDT to QDT; the mean time from KT to switch was 36.6 ± 16.1 months. In our study population, 4 patients received a living donor KT and 2 received a second allograft.Results
The mean follow-up was 86.8 ± 13 months from the switch and 126.2 ± 22.3 months from KT. Graft and patient survival rates were 90.2% and 95.1%, respectively. All patients maintained stable renal function during follow-up. During the first 3 months after the switch we observed a significant decrease in tacrolimus blood level (P = .0001). No significant differences were observed regarding tacrolimus dose before and after QDT introduction (P = not significant [NS]). Fourteen patients who stopped steroids under BDT treatment and 16 patients who stopped steroids after the switch are currently steroid-free.Conclusion
Our study showed safety and efficacy in switching from BDT to QDT. After early (<1 year) dose adjustment, tacrolimus blood levels remained stable throughout follow-up. Moreover, QDT represented a valid alternative for patients showing steroid side effects. 相似文献4.
5.
6.
Salvatore Sembronio Alberto Maria Albiero Massimo Robiony Fabio Costa Corrado Toro Massimo Politi 《Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics》2007,103(2):e1-e6
Septic arthritis of the temporomandibular joint (TMJ) is infrequently reported. We present a case of septic arthritis of the TMJ following the extraction of the left upper second molar that occurred 1 week before beginning of symptoms. No evident predisposing factors were detected. Arthroscopic diagnosis of septic arthritis, lysis and lavage, and capsular stretch were performed. Cultures taken from the TMJ space grew Streptococcus sp. After 1 month of antimicrobial therapy the patient was asymptomatic and mandibular function was normal. Literature related to septic arthritis of TMJ and its treatment was reviewed. Different surgical procedures are available to treat this condition. Arthroscopy should be preferred as initial treatment on account of the possibility of drainage and accurate lavage under direct visualization of joint space, at the same time allowing confirmation of diagnostic hypotheses. Improving joint mobility with lysis of adhesions and capsular stretch in an early stage of disease may be helpful in stopping the fibrosis process. 相似文献
7.
Giuseppina Di Stefano Luigi Fiume Michele Baglioni Corrado Busi Pasquale Chieco Felix Kratz Alessandro Mattioli 《European journal of pharmaceutical sciences》2007,30(2):136-142
Several attempts have been made to enhance doxorubicin (DOXO) concentrations in tumour cells by drug conjugation with human albumin (HSA). HSA-DOXO has the drawback of causing DOXO accumulation in spleen and bone marrow, with a consequent leucopoenia not produced when lactose molecules are coupled to the carrier protein. In the present experiments we demonstrated that the effect of HSA lactosamination is not a consequence of a more rapid disappearance from the bloodstream of the lactosaminated conjugate (L-HSA-DOXO), which is rapidly internalized by the liver through the asialoglycoprotein receptor, but is due to a hindered uptake by spleen and bone marrow cells caused by the coupled lactose molecules. Experiments in vitro showed that HSA-DOXO produced an inhibition of murine macrophage proliferation not caused by L-HSA-DOXO. This result can be explained by higher amounts of the former conjugate entering in these cells and suggests macrophages as the cell type responsible for the spleen and bone marrow internalization of HSA-DOXO hindered by lactose coupling. Importantly, lactosamination of HSA did not reduce the marked uptake of HSA-DOXO by chemically induced rat hepatocellular carcinoma. L-HSA-DOXO, by avoiding DOXO accumulation in bone marrow is an attractive candidate for clinical trials against tumors which were found to actively internalize this conjugate in laboratory animals, such as hepatocellular carcinoma. 相似文献
8.
9.
Among 315 cases of parenchymal renal carcinoma resected between 1975 and 1985, 19 cases (6 per cent) of sarcomatoid carcinoma were identified. All patients were symptomatic or had a palpable mass in the flank at hospitalization. Tumor stage generally was advanced at operation and metastases were detected in 8 patients (Robson stage IV), all of whom died after an average postoperative survival of 8 months. In 3 patients there was tumor invasion of the renal vein (Robson stage IIIA), and they died after an average postoperative period of 11 months. Of 4 patients with perinephric fat invasion (Robson stage II) 2 died of cancer after an average survival of 15 months and 2 are alive with no evidence of disease for an average of 73 months postoperatively. In these later 2 cases the sarcomatoid areas constituted less than 5 per cent of the entire tumor and the remaining tumor was low grade carcinoma. In 3 patients adequate followup is not available and 1 was lost to followup. This histological variant of parenchymal cell carcinoma is a high grade malignancy with a poor prognosis. Operative treatment appears to be ineffective in modifying the behavior of the tumor. 相似文献
10.
D. Mannini P. Maver E. Aiello G. Corrado F. Vecchi B. Bellanova M. Marengo 《Urological research》1988,16(1):9-12
Summary Spontaneous circadian variations of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP), determined simultaneously by radioimmunoassay (RIA), were investigated by multiple sampling, over a 24-hour period, in 32 patients with prostatic cancer. In 29/32 patients (91%), the coefficient of variation of 24-hour values, for either marker, was greater than that of the RIA method at the same range of values; stage D patients showed the greatest spontaneous variability. Fluctuations around the mean of 24-hour values ranged from-65% to +85% for PAP, from-72% to +190% for PSA, occurring random and independently for each marker. Variability was about 20% greater for PSA than for PAP. The existence of spontaneous fluctuations should be considered in multiple marker evaluation of prostatic cancer patients.Preliminary results of this study have been presented at the International Symposium on Hormonal Therapy of Prostatic Diseases —Basic and Clinical Aspects, April 6–8, 1987, Milan, Italy 相似文献